(Press-News.org) ALEXANDRIA, VA —The American Academy of Otolaryngology–Head and Neck Surgery Foundation published the Clinical Practice Guideline: Immunotherapy for Inhalant Allergy today in Otolaryngology–Head and Neck Surgery. This clinical practice guideline identifies quality improvement opportunities and provides clinicians trustworthy, evidence-based recommendations on the management of inhalant allergies with immunotherapy, supporting them to provide enhanced care to patients aged 5 years and older who are experiencing symptoms from inhalant allergies.
“More than 50 million Americans suffer from allergies annually. Despite the widespread use of allergen immunotherapy (AIT), there are multiple clinical dilemmas that exist, including patient selection, modes of immunotherapy delivery, and ongoing needs to evaluate and ensure the safety and efficacy of AIT,” said Richard K. Gurgel, MD, MSCI, Chair of the AAO-HNSF Guideline Development Group (GDG).
Allergen Immunotherapy is a type of treatment used to reduce allergy symptoms and improve quality of life. This is done by giving regular and repeated doses of an allergen (a substance that causes allergies) or allergens. Examples of allergens that can be inhaled include pet dander, pollen, ragweed, grass, and dust mites. By taking gradually increasing doses, the immune system builds up a tolerance and becomes less sensitive. Unlike other treatments, AIT can lead to lasting benefits even after stopping. This can reduce the need to take other medications, which provides cost savings and convenience. Additionally, there is evidence that AIT can reduce asthma symptoms and prevent asthma and new allergies from developing.
As patients, families, and caregivers consider immunotherapy as a treatment option, this guideline assists clinicians with an evidence-based framework for assessing patients’ care needs to provide immunotherapy as a treatment option if needed. The guideline provided 12 evidenced-based Key Action Statements (KAS) to guide clinicians in treating patients experiencing symptoms from inhalant allergies. The full KASs and the guideline with other supplemental materials can be found here: www.entnet.org/AITCPG
“The guideline development group used the AAO-HNSF rigorous, evidenced-based methodology to create high-quality recommendations on immunotherapy. We hope this CPG will be a valuable resource to optimize patient care and reduce unnecessary and costly variation in AIT management,” Dr. Gurgel remarked.
The GDG consisted of 17 panel members representing experts in otolaryngology and allergy or members who have expertise in clinical practice guideline development and a consumer/patient representative. Panel members came from a variety of practice settings, training backgrounds, and stages of training.
Members of the media who wish to request an interview or obtain a copy of the guideline should contact: Roland Buaben at 703-535-3768, or newsroom@entnet.org.
About the AAO-HNS/F
The AAO-HNS/F is one of the world’s largest organizations representing specialists who treat the ears, nose, throat, and related structures of the head and neck. Otolaryngologist–head and neck surgeons diagnose and treat medical disorders that are among the most common affecting patients of all ages in the United States and around the world. Those medical conditions include chronic ear disease, hearing and balance disorders, hearing loss, sinusitis, snoring and sleep apnea, allergies, swallowing disorders, nosebleeds, hoarseness, dizziness, and tumors of the head and neck as well as aesthetic and reconstructive surgery and intricate micro-surgical procedures of the head and neck. The Academy has approximately 13,000 members.
END
New clinical practice guideline provides evidence-based recommendations for immunotherapy for inhalant allergy
2024-02-26
ELSE PRESS RELEASES FROM THIS DATE:
SFU-led research team designs a cutting-edge protein lawnmower
2024-02-26
An SFU-led collaboration has designed the first synthetic protein-based motor which harnesses biological reactions to fuel and propel itself.
“Imagine if a Roomba could be powered only by the dirt it picks up,” says SFU Physics professor Nancy Forde, one of the authors of the study.
The team’s paper, led by SFU Physics PhD graduate Chapin Korosec and published today in Nature Communications, describes a protein-based molecular motor called “The Lawnmower,” which has been designed to cut a lawn of peptide “grass.” ...
Metal in glitter impairs aquatic plant growth, study shows
2024-02-26
Glitter is used in a wide array of colors and shapes in apparel, footwear, cosmetics, makeup, handbags, festive decorations, arts and crafts, and jewelry, among many other applications. During the Carnival holidays, hundreds of thousands of Brazilians cover parts of their bodies with it while dancing in the streets. Its brilliance is dazzling but it is considered an emerging pollutant by many scientists: like other microplastics (small plastic pieces less than 5 mm long), it is not filtered by wastewater treatment plants and ends up in rivers and the sea, interfering with aquatic life in various ways.
A study conducted at the Federal University of ...
Scientists assemble a richer picture of the plight and resilience of the foothill yellow-legged frog
2024-02-26
(Santa Barbara, Calif.) — Up to only a few inches in length, with a lemon-hued belly, the foothill yellow-legged frog may seem unassuming. But its range once stretched from central Oregon to Baja California. In 2023, it was listed under the federal Endangered Species Act. Its rapidly decreasing range is due in part to a fungal pathogen called Batrachochytrium dendrobatidis, or Bd, that has devastated amphibians around the world.
A team of researchers, including UC Santa Barbara’s Andrea Adams, has conducted the most comprehensive study to date ...
Neuropsychiatric symptoms predict which patients with mild cognitive impairment develop Alzheimer’s disease.
2024-02-26
As the years add up, it's common to notice slight changes in our ability to remember and think. Older people who have more marked changes than their peers can be diagnosed with mild cognitive impairment (MCI). Currently, we can’t easily predict which of these patients will develop Alzheimer’s disease and which will not.
“It's hard to predict which patients will have a more rapid progression and receive a diagnosis of dementia,” said Maria Vittoria Spampinato, M.D., division director of Neuroradiology at the Medical University of South Carolina.
“It’s important ...
Resurrecting niobium for quantum science
2024-02-26
For years, niobium was considered an underperformer when it came to superconducting qubits. Now scientists supported by Q-NEXT have found a way to engineer a high-performing niobium-based qubit and so take advantage of niobium’s superior qualities.
When it comes to quantum technology, niobium is making a comeback.
For the past 15 years, niobium has been sitting on the bench after experiencing a few mediocre at-bats as a core qubit material.
Qubits are the fundamental components of quantum devices. One qubit type relies on superconductivity to process information.
Touted for its superior qualities as a superconductor, niobium was always a promising ...
Long-term data reveals SARS-CoV-2 infection and vaccine-induced antibody responses are long-lasting
2024-02-26
A long-term analysis conducted by leading microbiologists at the Icahn School of Medicine at Mount Sinai reveals that antibody responses induced by COVID-19 vaccines are long-lasting. The study results, published online in the journal Immunity on February 22, challenge the idea that mRNA-based vaccine immunity wanes quickly.
The emergence of SARS-CoV-2, the virus that causes COVID-19, in late 2019 sparked the global pandemic that is now in its fifth year. Vaccines that were developed at record speed have saved millions of lives. However, the emergence of SARS-CoV-2 variants and waning immunity have decreased ...
Shaping the future of phage therapy: The 7th World Conference on Targeting Phage Therapy in Malta aims to transform clinical trials through translational research
2024-02-26
The 7th World Conference on Targeting Phage Therapy 2024, two-day event dedicated to advancing the field of phage research and therapy will be hosted at Corinthia Palace Malta on June 20-21.
Robert T. Schooley, M.D., Professor of Medicine at the University of California, San Diego, Co-Director of the Center for Innovative Phage Applications and Therapeutics, and member of the Executive Committee for the University of California Disaster Resilience Network, will introduce the messages and strategies behind phages therapy 2024.
His talk titled “Phage Therapeutics 2024: Essential Translational Research Components for ...
GZ17-6.02 with bexarotene kills mycosis fungoides cells
2024-02-26
“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.”
BUFFALO, NY- February 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”
In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from Virginia Commonwealth University and Genzada Pharmaceuticals investigated the therapeutic agent GZ17-6.02, composed of curcumin, ...
University of Tennessee Health Science Center professor awarded $1.5m to study 'root causes' of disparity in breast cancer survival of Black women and white women
2024-02-26
Memphis, Tenn. (February 26, 2024) – Shelley White-Means, PhD, a professor of Health Economics in the Department of Interprofessional Education and the director of the Consortium for Health Education, Economic Empowerment and Research (CHEER) at UT Health Science Center, recently received a $1.5 million, four-year grant from the National Institute on Minority Health and Health Disparities to explore the root causes of the disparity in breast cancer survival of Black women compared to white women.
Dr. White-Means and a team will look beyond the social determinants of health to explore what she terms “the intersectionality of race, ...
Steering and accelerating electrons at the microchip scale
2024-02-26
Stanford researchers are getting closer to building a tiny electron accelerator based on “accelerator-on-a-chip” technology with broad potential applications in studying physics as well as medical and industrial uses.
The researchers have demonstrated that a silicon dielectric laser accelerator, or DLA, can now both speed up and confine electrons, creating a focused beam of high-energy electrons. “If the electrons were microscopic cars, it’s as if, for the first time, we’re steering and we have our foot on the gas,” said Payton Broaddus, PhD ’23 in electrical engineering and the lead author on a paper published on ...